MarketLens

Did Recursion Pharmaceuticals' Q4 Beat Signal a Turning Point

8 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in

SHARE THIS ON:

Did CF Industries' Q4 2025 Earnings Beat Signal a Turning Point

8 months ago

Did Marvell Technology's Q4 Earnings Signal a Turning Point for Investors

7 months ago

Did Magna International's Q4 2025 Earnings Signal a Turning Point

8 months ago

Did Hecla Mining's Q4 2025 Earnings Signal a Turning Point

8 months ago

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Recursion priced a $200M underwritten offering of 61.54M Class A shares at $3.25 each, with all proceeds going to the company. The raise adds capital but dilutes existing holders by roughly 15% based ...

RXRX

Stock News•1 months ago

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Recursion Pharmaceuticals (RXRX) rose 8.2% since its earnings report 30 days ago, driven by investor reaction to the results. The stock's next move may hinge on upcoming catalysts and pipeline updates...

RXRX

Stock News•3 months ago

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

Recursion Pharmaceuticals reported a 46% revenue jump and its first recurring platform contracts, as its AI-driven drug discovery pivot begins showing financial results.

HYFT